{"transactions":[{"id":2444633,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":131630,"kind":"person","name":"Rabinowitz Michael","position":1,"cik":"0001767090","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T01:38:10.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option will vest in 4 installments as follows: 8,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026."}],"balance_after":32000,"derivative":{"exercise_price":13.89,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001213900-22-000814","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022000814/ownership.xml","form_type":"4"}},{"id":2444632,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":131630,"kind":"person","name":"Rabinowitz Michael","position":1,"cik":"0001767090","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-06T01:38:10.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":19000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents Restricted Stock Units (\"RSUs\") that will vest in 4 installments as follows: 4,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis."}],"balance_after":109468,"source":{"system":"sec-edgar","filing":"0001213900-22-000814","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390022000814/ownership.xml","form_type":"4"}},{"id":2456309,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":131630,"kind":"person","name":"Rabinowitz Michael","position":1,"cik":"0001767090","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-31T02:30:54.000Z","date":"2021-12-28","kind":"tax_withholding","acquired":false,"shares":9532,"price":12.98,"value":123725.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Payment of tax liability by withholding securities incident to the vesting of the issued security."}],"balance_after":90468,"source":{"system":"sec-edgar","filing":"0001213900-21-068230","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390021068230/ownership.xml","form_type":"4"}},{"id":2611808,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":131630,"kind":"person","name":"Rabinowitz Michael","position":1,"cik":"0001767090","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-06T20:01:21.000Z","date":"2021-08-04","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Stock Options will vest in five installments as follows: 12,500 shall vest on December 31, 2021, 25,000 shall vest on each of December 31, 2022, December 31, 2023 and December 31, 2024, and 12,500 shall vest on August 4, 2025."}],"balance_after":100000,"derivative":{"exercise_price":15.1,"expiration_date":"2031-08-04","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-21-040761","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390021040761/ownership.xml","form_type":"4"}},{"id":2611807,"issuer":{"id":6311,"kind":"organization","name":"ORAMED PHARMACEUTICALS INC.","symbol":"ORMP"},"owners":[{"id":131630,"kind":"person","name":"Rabinowitz Michael","position":1,"cik":"0001767090","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-08-06T20:01:21.000Z","date":"2021-08-04","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents common stock underlying Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"date","element":"transactionDate","label":"F2","text":"The RSUs will vest as follows: 33,333 shall vest if the closing price per share of the Issuer's common stock will be $15 for at least 20 days, 33,333 shall vest if the closing price per share of the Issuer's common stock will be $25 for at least 20 days, and 33,334 shall vest if the Issuer consummates an arm's length licensing or other strategic transaction, that includes its phase 3 oral insulin product, for no less than $50,000,000 in upfront cash (including proceeds from any upfront stock equity purchase)."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001213900-21-040761","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390021040761/ownership.xml","form_type":"4"}},{"id":3477864,"issuer":{"id":132434,"kind":"organization","name":"LGBTQ Loyalty Holdings, Inc.","symbol":"LFAP"},"owners":[{"id":156457,"kind":"organization","name":"Maxim Partners LLC","position":1,"cik":"0001503205","reported_name":"Maxim Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":156458,"kind":"organization","name":"MJR Holdings LLC","position":2,"cik":"0001503206","reported_name":"MJR Holdings LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":131630,"kind":"person","name":"Rabinowitz Michael","position":3,"cik":"0001767090","reported_name":"Rabinowitz Michael","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T14:10:44.000Z","date":"2019-06-04","kind":"other","acquired":false,"shares":120959996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Maxim Partners LLC entered into a securities exchange agreement with LGBTQ Loyalty Holdings, Inc. pursuant to which the Maxim Partners LLC exchanged 129,558,574 shares of Common Stock for 129,559 shares (the \"Exchange Shares\") of our Series C Preferred Stock (the \"Share Exchange\"). At the request of the Maxim Partners LLC, the Exchange Shares were transferred and issued to Pride Partners LLC, an affiliate of Maxim Partners LLC."},{"field":"shares","element":"transactionShares","label":"F1","text":"All of the securities reported herein were owned directly by Maxim Partners LLC (\"Maxim Partners\") and 79% of the securities reported herein, or 95,558,397 shares, were indirectly owned by MJR Holdings LLC (\"MJR\") which owns 79% of the membership interests in Maxim Partners and Michael Rabinowitz is the principal of MJR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001213900-19-011499","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1503205/000121390019011499/ownership.xml","form_type":"4"}}]}